Different surgical approaches for recurrent lumbar disc herniation after percutaneous endoscopic transforaminal discectomy: analysis of clinical and imaging outcomes

经皮内镜椎间孔入路椎间盘切除术后复发性腰椎间盘突出症的不同手术入路:临床和影像学结果分析

阅读:3

Abstract

OBJECTIVE: We compared the clinical efficacy of different surgical approaches for recurrent lumbar disc herniation (RLDH) after percutaneous endoscopic transforaminal discectomy (PETD). METHODS: Eighty-seven patients with RLDH were included between June 2013 and June 2022, of whom 38 underwent percutaneous endoscopic interlaminar discectomy (PEID) and 49 underwent PETD again. We compared perioperative variables as well as clinical and imaging outcomes. Clinical evaluations consisted of visual analog scale for back pain (VAS-B) and leg pain (VAS-L), Japanese Orthopedic Association score (JOA), and Oswestry disability index (ODI). Imaging measurements consisted of disc height index (DHI), range of motion (ROM), and sagittal translation (ST). RESULTS: Compared to the PETD group, the PEID group presented shorter operative time and fewer fluoroscopy times (P < 0.05); nevertheless, intraoperative blood loss, hospital stay, incision length, and the complication rate showed no significant between-group difference (P > 0.05). Both groups showed significant clinical improvement postoperatively (P < 0.05). At 7 days after surgery, VAS-B, VAS-L, JOA, and ODI showed greater improvement in the PEID group compared with the PETD group (P < 0.05). There were no significant between-group differences in imaging data (P > 0.05). Postoperative ROM and ST remained below instability thresholds, and no lumbar instability was observed. CONCLUSION: For patients with RLDH after PETD, both PEID and PETD achieve satisfactory clinical efficacy. PEID provides advantages over PETD by reducing operative time and fluoroscopy, and is effective in avoiding scar tissue formation from initial surgery. These findings suggest that PEID may be preferable in selected recurrent cases, particularly where scar tissue or anatomical barriers compromise transforaminal access.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。